By integrating the SNORic database with breast cancer subtypes and updated clinical outcomes, we found that Snord67 expression was significantly increased in the basal and luminal B subtypes, which are among the most clinically aggressive subtypes of breast cancer, compared to the luminal A subtype, which is associated with better prognosis (Supplemental Fig. 12B). Here, SNORD67 is linked to breast carcinoma.